Novo Nordisk Granted US Patent for Pill Design

The USPTO has granted Novo Nordisk A/S a US design patent for a pill design. The patent, identified as USD1120291S1, was granted on March 24, 2026, with a filing date of May 30, 2024.

USPTO Patent Granted for Pharmaceutical Tablet Design

The USPTO has granted a new patent (USD1120290S1) for a pharmaceutical tablet design to Eli Lilly and Company. The patent, which covers a specific design for a tablet, was filed in 2020 and officially granted on March 24, 2026.

Vaccine against Leptospira bacterium patent EP4709415A1

The European Patent Office has published patent application EP4709415A1 for a vaccine against the Leptospira bacterium. The patent is assigned to Intervet International B.V. and lists Antonius Arnoldus Christiaan Jacobs as the inventor. The publication date is March 18, 2026.

EPO Patent: Vaccine against Erysipelothrix Rhusiopathiae and Porcine Parvo Virus

The European Patent Office has published patent application EP4709414A1 for a vaccine against Erysipelothrix Rhusiopathiae and Porcine Parvo Virus. The patent was filed by Intervet International B.V. and is designated for several European states.

Vaccine EP4709413A1 against Erysipelothrix, Porcine Parvo, Leptospira

The European Patent Office has published patent application EP4709413A1 for a combination vaccine developed by Intervet International B.V. This patent covers a vaccine designed to protect against Erysipelothrix rhusiopathiae, Porcine Parvo virus, and Leptospira bacterium.

Sanofi Pasteur RSV Vaccine Patent Application

The European Patent Office has published a patent application (EP4709418A1) filed by Sanofi Pasteur Inc. for a Respiratory Syncytial Virus (RSV) vaccine. The application lists inventors from Sanofi Pasteur and the U.S. Department of Health and Human Services.

EPO Patent Publication: Oral Therapeutic Compounds Inhibiting HMG-CoA Reductase

The European Patent Office has published patent application EP4709402A1 for oral therapeutic compounds designed to inhibit HMG-CoA reductase enzyme activity. The application lists Difass International S.p.A. as the applicant.

EPO Patent Publication: Oligosaccharide Compounds for Neuro-Ischemic Wounds in Diabetics

The European Patent Office has published patent application EP4709393A1 concerning the use of oligosaccharide compounds to prevent the recurrence of neuro-ischemic wounds in diabetic patients. The patent application lists URGO RECHERCHE INNOVATION ET DEVELOPPEMENT as the applicant.

Foghorn Therapeutics Therapeutic Compounds Patent Publication

The European Patent Office has published patent application EP4709726A1 by Foghorn Therapeutics Inc. for therapeutic compounds. The publication includes details on the applicants, inventors, and International Patent Classification codes related to the compounds and their uses.

Mirati Therapeutics Files Patent for Substituted Quinoxalines

The European Patent Office has published patent application EP4709714A1 filed by Mirati Therapeutics, Inc. for substituted quinoxalines. This publication relates to potential new therapeutic compounds.